CL2018002797A1 - Receptores quiméricos y métodos de uso de los mismos. - Google Patents

Receptores quiméricos y métodos de uso de los mismos.

Info

Publication number
CL2018002797A1
CL2018002797A1 CL2018002797A CL2018002797A CL2018002797A1 CL 2018002797 A1 CL2018002797 A1 CL 2018002797A1 CL 2018002797 A CL2018002797 A CL 2018002797A CL 2018002797 A CL2018002797 A CL 2018002797A CL 2018002797 A1 CL2018002797 A1 CL 2018002797A1
Authority
CL
Chile
Prior art keywords
methods
chimeric receptors
cll
union
antigen
Prior art date
Application number
CL2018002797A
Other languages
English (en)
Inventor
Jed Wiltzius
Rodriguez Ruben Alvarez
Tara Arvedson
Alice Bakker
Lawren Wu
Original Assignee
Kite Pharma Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc, Amgen Inc filed Critical Kite Pharma Inc
Publication of CL2018002797A1 publication Critical patent/CL2018002797A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Abstract

LAS MOLÉCULAS DE UNIÓN AL ANTÍGENO, LOS RECEPTORES QUIMÉRICOS Y LAS CÉLULAS INMUNES MANIPULADAS PARA CLL–1 SE DESCRIBEN DE ACUERDO CON LA INVENCIÓN. LA INVENCIÓN SE REFIERE ADEMÁS A VECTORES, COMPOSICIONES Y MÉTODOS DE TRATAMIENTO Y/O DETECCIÓN UTILIZANDO LAS MOLÉCULAS DE UNIÓN AL ANTÍGENO DE CLL–1 Y LAS CÉLULAS INMUNES MANIPULADAS.
CL2018002797A 2016-04-01 2018-10-01 Receptores quiméricos y métodos de uso de los mismos. CL2018002797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317068P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
CL2018002797A1 true CL2018002797A1 (es) 2020-06-12

Family

ID=59960746

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2018002797A CL2018002797A1 (es) 2016-04-01 2018-10-01 Receptores quiméricos y métodos de uso de los mismos.
CL2019002310A CL2019002310A1 (es) 2016-04-01 2019-08-14 Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
CL2020002677A CL2020002677A1 (es) 2016-04-01 2020-10-15 Receptores quiméricos y metodos de uso de los mismos(divisional de solicitud 2310-2019)
CL2021001750A CL2021001750A1 (es) 2016-04-01 2021-06-30 Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020)
CL2022001873A CL2022001873A1 (es) 2016-04-01 2022-07-08 Receptores quiméricos y metodos de uso de los mismos

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2019002310A CL2019002310A1 (es) 2016-04-01 2019-08-14 Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
CL2020002677A CL2020002677A1 (es) 2016-04-01 2020-10-15 Receptores quiméricos y metodos de uso de los mismos(divisional de solicitud 2310-2019)
CL2021001750A CL2021001750A1 (es) 2016-04-01 2021-06-30 Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020)
CL2022001873A CL2022001873A1 (es) 2016-04-01 2022-07-08 Receptores quiméricos y metodos de uso de los mismos

Country Status (32)

Country Link
US (3) US10597456B2 (es)
EP (2) EP3436030B1 (es)
JP (4) JP2019513370A (es)
KR (5) KR20200068750A (es)
CN (2) CN109641008B (es)
AR (1) AR108066A1 (es)
AU (3) AU2017240788B2 (es)
BR (1) BR112018070260A2 (es)
CA (2) CA3177398A1 (es)
CL (5) CL2018002797A1 (es)
CO (1) CO2018010547A2 (es)
CR (2) CR20210084A (es)
DK (1) DK3436030T3 (es)
EA (1) EA201891992A1 (es)
ES (1) ES2930058T3 (es)
HR (1) HRP20221348T1 (es)
HU (1) HUE060645T2 (es)
IL (1) IL262041A (es)
LT (1) LT3436030T (es)
MA (1) MA43603A1 (es)
MX (2) MX2018012019A (es)
MY (1) MY197669A (es)
PE (3) PE20211418A1 (es)
PH (1) PH12018502113A1 (es)
PL (1) PL3436030T3 (es)
PT (1) PT3436030T (es)
RS (1) RS63735B1 (es)
SG (2) SG10201912519VA (es)
SI (1) SI3436030T1 (es)
TW (4) TWI714470B (es)
UA (1) UA123276C2 (es)
WO (1) WO2017173384A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505613B2 (en) 2016-04-01 2022-11-22 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2017242893A1 (en) 2016-03-31 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
AU2017240667C1 (en) * 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
UA125407C2 (uk) 2017-05-22 2022-03-02 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
WO2019099707A1 (en) * 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
CA3117759A1 (en) * 2018-10-26 2020-04-30 Cafa Therapeutics Limited Cll1-targeting antibody and application thereof
CA3131908A1 (en) 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Dll3 targeting chimeric antigen receptors and binding agents
EP3966236A4 (en) * 2019-05-07 2023-05-10 The Board of Trustees of the Leland Stanford Junior University IMPROVEMENT OF POLYPEPTIDES AND CHIMERA ANTIGEN RECEPTORS ACROSS HINGE DOMAINS
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
EP4028031A4 (en) * 2019-09-13 2023-09-06 Memorial Sloan Kettering Cancer Center CD371 TARGETING ANTIGEN RECOGNIZING RECEPTORS AND USES THEREOF
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
CN113416713A (zh) * 2021-05-11 2021-09-21 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种重组腺病毒的构建及其应用
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
WO2024044670A1 (en) 2022-08-26 2024-02-29 Kite Pharma, Inc. Improving immune cell function
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6892139B2 (en) 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP2322547A1 (en) * 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2006028785A2 (en) 2004-09-03 2006-03-16 General Motors Corporation Aligning method for repeating and non-repeating units in a fuel cell stack
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
JP6061469B2 (ja) 2009-03-10 2017-01-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗ｂｃｍａ抗体
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2780707A1 (en) 2009-11-17 2011-05-26 Basf Plant Science Company Gmbh Plants with increased yield
WO2011138414A1 (en) 2010-05-05 2011-11-10 Addex Pharma Sa Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
US9493740B2 (en) 2010-09-08 2016-11-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered GD2-specific T cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP3305798A1 (en) 2010-12-09 2018-04-11 The Trustees of The University of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2824997C (en) 2011-01-18 2023-01-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
WO2012103279A2 (en) 2011-01-26 2012-08-02 Ariad Pharmaceuticals, Incorporated Methods and compositions for the synthesis of multimerizing agents
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
HUE063461T2 (hu) 2011-05-27 2024-01-28 Glaxo Group Ltd BCMA (CD269/TNFRSF17)-kötõ fehérjék
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
DE102012204596A1 (de) 2012-03-22 2013-09-26 Ford Global Technologies, Llc Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs
CA3116051C (en) 2012-03-23 2023-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
SG11201406414WA (en) 2012-04-11 2014-11-27 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2953475B1 (en) 2013-02-06 2019-07-03 Celgene Corporation Modified t lymphocytes having improved specificity
CN105142677B (zh) 2013-02-15 2019-08-30 加利福尼亚大学董事会 嵌合抗原受体及其使用方法
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6543626B2 (ja) 2013-07-29 2019-07-10 ブルーバード バイオ， インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
CA2930587A1 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR20220119176A (ko) 2014-02-04 2022-08-26 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
JP6772063B2 (ja) 2014-02-14 2020-10-21 ベリカム ファーマシューティカルズ， インコーポレイテッド 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
RU2741120C2 (ru) * 2014-07-21 2021-01-22 Новартис Аг Лечение рака с использованием химерного антигенного рецептора cll-1
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
KR102523934B1 (ko) 2014-07-24 2023-04-20 2세븐티 바이오, 인코포레이티드 Bcma 키메릭 항원 수용체
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CN107002084B (zh) 2014-09-19 2021-09-10 希望之城公司 靶向IL13Rα2的共刺激嵌合抗原受体T细胞
CA2969704C (en) 2014-12-05 2023-05-02 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells
EP3230321B1 (en) 2014-12-12 2019-08-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
CN107980046B (zh) 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
EP3283106B1 (en) 2015-04-13 2021-12-22 Pfizer Inc. Therapeutic antibodies and their uses
AU2017240667C1 (en) 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
WO2017173410A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
CN116425876A (zh) 2016-04-01 2023-07-14 凯德药业股份有限公司 Bcma结合分子及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505613B2 (en) 2016-04-01 2022-11-22 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof

Also Published As

Publication number Publication date
JP2024069310A (ja) 2024-05-21
KR20220157517A (ko) 2022-11-29
JP2019513370A (ja) 2019-05-30
US20200115457A1 (en) 2020-04-16
UA123276C2 (uk) 2021-03-10
KR20180129889A (ko) 2018-12-05
TW202041529A (zh) 2020-11-16
CN113150170A (zh) 2021-07-23
PE20200400A1 (es) 2020-02-26
AU2020203990A1 (en) 2020-07-02
WO2017173384A1 (en) 2017-10-05
EP4180449A1 (en) 2023-05-17
MA43603A1 (fr) 2019-03-29
JP7134204B2 (ja) 2022-09-09
CA3177398A1 (en) 2017-10-05
IL262041A (en) 2018-11-29
AR108066A1 (es) 2018-07-11
DK3436030T3 (da) 2022-11-21
RS63735B1 (sr) 2022-12-30
CA3019650A1 (en) 2017-10-05
MY197669A (en) 2023-07-03
LT3436030T (lt) 2022-12-12
HRP20221348T1 (hr) 2023-01-06
PH12018502113A1 (en) 2019-09-23
CA3019650C (en) 2023-07-25
TWI714470B (zh) 2020-12-21
BR112018070260A2 (pt) 2019-01-29
CL2019002310A1 (es) 2019-12-20
JP7451627B2 (ja) 2024-03-18
SI3436030T1 (sl) 2023-01-31
KR102120815B1 (ko) 2020-06-12
SG11201808595WA (en) 2018-10-30
MX2018012019A (es) 2019-07-10
TW202319537A (zh) 2023-05-16
KR20230165383A (ko) 2023-12-05
CR20210084A (es) 2021-03-26
KR102608405B1 (ko) 2023-12-01
JP2020202867A (ja) 2020-12-24
CN109641008B (zh) 2021-03-23
ES2930058T3 (es) 2022-12-05
EP3436030B1 (en) 2022-08-24
CL2021001750A1 (es) 2022-01-28
JP2022169740A (ja) 2022-11-09
MX2023002556A (es) 2023-03-22
PL3436030T3 (pl) 2022-12-19
US20230331855A1 (en) 2023-10-19
SG10201912519VA (en) 2020-02-27
PE20211418A1 (es) 2021-08-02
KR20200068750A (ko) 2020-06-15
CO2018010547A2 (es) 2019-02-08
AU2023208077A1 (en) 2023-08-17
EP3436030A4 (en) 2019-11-06
KR20210089262A (ko) 2021-07-15
CL2022001873A1 (es) 2023-05-26
EP3436030A1 (en) 2019-02-06
AU2017240788B2 (en) 2020-04-09
AU2017240788A1 (en) 2018-11-01
TWI792123B (zh) 2023-02-11
PT3436030T (pt) 2022-11-18
CN109641008A (zh) 2019-04-16
PE20190356A1 (es) 2019-03-07
US10597456B2 (en) 2020-03-24
CR20180480A (es) 2019-04-02
EA201891992A1 (ru) 2019-08-30
TW202130657A (zh) 2021-08-16
TW201803896A (zh) 2018-02-01
US20170283500A1 (en) 2017-10-05
HUE060645T2 (hu) 2023-04-28
CL2020002677A1 (es) 2021-01-29

Similar Documents

Publication Publication Date Title
CL2018002797A1 (es) Receptores quiméricos y métodos de uso de los mismos.
CL2018002792A1 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos.
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CO2019007288A2 (es) Anticuerpos anti-ox40 y sus usos
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CR20160379A (es) Anticuerpos biespecificos anti-il 13/il-17 y sus usos
CL2023003182A1 (es) Receptores químericos de steap1 y métodos de uso de los mismos
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
CL2021001441A1 (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932)
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos
EA201890727A1 (ru) Модуляторы взаимодействия сестрина-gator2 и их применение
BR112017010627A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças